Sorrento Therapeutics (SRNE) Getting Somewhat Positive News Coverage, Report Shows
News headlines about Sorrento Therapeutics (NASDAQ:SRNE) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.1582572161802 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Sorrento Therapeutics Inc (SRNE) Has Competitive Advantage to Claim Meaningful Share in Lidocaine Patch Market, Cheers H.C. Wainwright (smarteranalyst.com)
- H.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE) (finance.yahoo.com)
- Sorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by HC Wainwright (americanbankingnews.com)
- Technical Insights on Biotech Stocks — Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics (bizjournals.com)
- Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors (thestreet.com)
Several equities analysts recently commented on the company. FBR & Co reiterated a “buy” rating on shares of Sorrento Therapeutics in a research note on Saturday, June 17th. Oppenheimer Holdings, Inc. set a $7.00 target price on Sorrento Therapeutics and gave the company a “buy” rating in a research note on Tuesday, August 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Sorrento Therapeutics in a research note on Monday, September 18th. Roth Capital initiated coverage on Sorrento Therapeutics in a research note on Thursday, August 3rd. They issued a “buy” rating and a $7.00 target price for the company. Finally, UBS AG initiated coverage on Sorrento Therapeutics in a research report on Thursday, August 3rd. They set an “outperform” rating and a $7.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Sorrento Therapeutics presently has an average rating of “Buy” and a consensus target price of $11.67.
Sorrento Therapeutics (SRNE) remained flat at $1.80 during midday trading on Friday. 1,177,827 shares of the stock were exchanged. The stock’s market capitalization is $124.15 million. Sorrento Therapeutics has a 52-week low of $1.50 and a 52-week high of $7.84. The company has a 50 day moving average of $1.76 and a 200-day moving average of $2.03.
COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/sorrento-therapeutics-srne-getting-somewhat-positive-news-coverage-report-shows/1615918.html.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.